Today: 11 June 2026
Morgan Stanley stock heads into Monday after a 2.3% jump — here’s what traders watch next
8 February 2026
1 min read

Morgan Stanley stock heads into Monday after a 2.3% jump — here’s what traders watch next

New York, Feb 8, 2026, 14:26 (ET) — The market has wrapped up for the day.

  • Morgan Stanley climbed 2.3% Friday, ending its three-day slide.
  • Wall Street’s strong rally pushed the Dow past 50,000 at the close, marking its first finish above that level.
  • Coming up for investors: delayed U.S. jobs and inflation numbers land Friday. Morgan Stanley, meanwhile, won’t report results until April.

Morgan Stanley’s stock settled at $179.96 Friday, up 2.3%. Shares moved within a $175.52 to $181.17 band during the session. The last open was $178.89.

U.S. markets being closed on Sunday leaves investors heading into Monday’s open with that move top of mind. Unclear for now: was Friday’s bounce just a quick relief rally, or the first sign of a more sustained push into large financial stocks?

Morgan Stanley depends heavily on lively markets and investor confidence. Trading, dealmaking, and the wealth management division’s client assets all swing with those forces. If investors shift gears, the bank tends to notice in short order.

The rally Friday swept across the board. Dow Jones Industrial Average topped 50,000 for the first time ever, with investors shifting money out of crowded tech and AI trades after a rough stretch for several software stocks. “What’s driven it recently has been the broadening that we have seen in the market,” said Chuck Carlson, chief executive officer at Horizon Investment Services. Reuters

Morgan Stanley’s advance trailed rivals. JPMorgan Chase jumped 3.95% for the day, Wells Fargo picked up 2.63%, and Charles Schwab added 3.02%. Still, Morgan Stanley’s shares remain roughly 6.6% off their recent 52-week high, MarketWatch data show.

Bank stock traders watch bond yields closely — a quick read on where rates might be headed. When rate expectations drop, risk assets and dealmaking often get a lift. On the flip side, that same move can pinch net interest income, narrowing the gap between what banks earn from loans and what they pay out for funding.

Friday’s run could stall if upcoming U.S. data stirs up inflation concerns again. Stronger-than-expected inflation would likely send yields up, threatening the “soft landing” narrative that fueled last week’s rally.

Morgan Stanley set its Q1 2026 investor call for April 15, with earnings set to drop around 7:30 a.m. ET that morning, according to a previous statement from the bank.

First up, Friday brings the next major catalyst. With the government’s disrupted economic calendar, core data points are now stacked, and the Bureau of Labor Statistics lists the postponed January jobs report and the January CPI as both landing at 8:30 a.m. ET on Feb. 13. That double release has the potential to jolt yields, spark shifts in rate-cut bets, and send bank stocks moving fast.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open
Previous Story

JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view
Next Story

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view

Go toTop